Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

490 recalls · Class II, newest first

Class II · Moderate risk

Product label: Temozolomide Capsules

Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing

Ongoing Impurity / degradation Rising Pharma Holding, Inc. NDC 16571-816-51 D-0384-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0386-2026
Class II · Moderate risk

Five-Star

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0385-2026
Class II · Moderate risk

Semaglutide

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Ongoing Microbial contamination Harbin Jixianglong Biotech Co., Ltd. NDC 84385-106-01 D-0380-2026
Class II · Moderate risk

Semaglutide

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Ongoing Microbial contamination Harbin Jixianglong Biotech Co., Ltd. NDC 84385-106-01 D-0379-2026
Class II · Moderate risk

Amantadine HCl

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Ongoing Dissolution failure AvKARE NDC 50268-069-15 D-0341-2026
Class II · Moderate risk

Adbry

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Ongoing Sterility / contamination Leo Pharma INC NDC 50222-350-91 D-0339-2026

Recalls by year